March 13 (Reuters) – British drugmaker GSK said on Friday the U.S. Food and Drug Administration has expanded the approved age range for its respiratory syncytial virus vaccine, Arexvy, to include adults aged 18 to 49 who are at increased risk of lower respiratory tract disease caused by the virus.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Devika Syamnath)
Comments